Pasithea Therapeutics Corp.(KTTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KTTA Pasithea Therapeutics Corp.

Trading 03-20 14:51:16 EDT

0.8043

+0.0222

+2.84%

High0.8117	Low0.7576	Vol118.86K
Open0.7650	D1 Closing0.7821	Amplitude6.92%
Mkt Cap18.57M	Tradable Cap14.89M	Total Shares23.09M
T/O92.87K	T/O Rate0.64%	Tradable Shares18.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KTTA","market":"US","secType":"STK","nameCN":"Pasithea Therapeutics Corp.","latestPrice":0.8043,"timestamp":1774032674655,"preClose":0.7821,"halted":0,"volume":118856,"delay":0,"changeRate":0.028385116992711925,"floatShares":18518700,"shares":23091062,"eps":-5.2115,"marketStatus":"Trading","change":0.0222,"latestTime":"03-20 14:51:16 EDT","open":0.765,"high":0.8117,"low":0.7576,"amount":92865.0096872,"amplitude":0.069173,"askPrice":0.8191,"askSize":500,"bidPrice":0.7894,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-5.2115,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774036800000},"marketStatusCode":2,"adr":0,"listingDate":1628654400000,"exchange":"NASDAQ","adjPreClose":0.7821,"preHourTrading":{"tag":"盘前","latestPrice":0.7821,"preClose":0.7821,"latestTime":"08:00 EDT","volume":11,"amount":8.55100026,"timestamp":1774008002525,"change":0,"changeRate":0,"amplitude":0.066616},"postHourTrading":{"tag":"盘后","latestPrice":0.7821,"preClose":0.7821,"latestTime":"19:55 EDT","volume":11,"amount":8.415,"timestamp":1773964521794,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.784244},"requestUrl":"/m/hq/s/KTTA/tweets","defaultTab":"tweets","newsList":[{"id":"2613521848","title":"Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2613521848","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613521848?lang=en_us&edition=fundamental","pubTime":"2026-02-21 06:36","pubTimestamp":1771626999,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp ( ($KTTA) ) has provided an update. On February 20, 2026, Pasithea Therapeutics received a Nasdaq notice that its common...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pasithea-therapeutics-receives-nasdaq-minimum-bid-price-notice?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pasithea-therapeutics-receives-nasdaq-minimum-bid-price-notice?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2613904682","title":"Nasdaq flags Pasithea Therapeutics for failing $1 minimum bid rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2613904682","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613904682?lang=en_us&edition=fundamental","pubTime":"2026-02-21 06:01","pubTimestamp":1771624887,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp. said it received a Nasdaq notice stating it is not in compliance with the exchange’s $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company has until August 19, 2026 to regain compliance, generally by maintaining a closing bid price at or above $1.00 for at least 10 consecutive business days, and it may seek an additional compliance period if eligible.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 20, 2026, and is solely respo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL84GF1g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2612519974","title":"Pasithea Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2612519974","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612519974?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:02","pubTimestamp":1771329728,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corporation  will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, from 4:00-4:30 PM ET in Track 2. The virtual presentation by CEO Tiago Reis Marques can be accessed through a live webcast on the Events page in the Investors section of the Company's website, with a replay available following the event. The webcast may be viewed here.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via GlobeNewswire  on February 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL890MjR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","SG9999014005.SGD","KTTA","LU2095319765.USD","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4139","SG9999014013.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2607728940","title":"Pasithea Therapeutics Corporation Held Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2607728940","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607728940?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:19","pubTimestamp":1769635150,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corporation held a Special Meeting of Stockholders on January 28, 2026. Stockholders approved an amendment to increase the number of authorized shares of common stock from 100,000,000 to 500,000,000. An amendment to the 2023 Stock Incentive Plan, increasing the number of shares authorized for issuance under the plan, was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL32vqKj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2603184536","title":"Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2603184536","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603184536?lang=en_us&edition=fundamental","pubTime":"2026-01-14 19:56","pubTimestamp":1768391813,"startTime":"0","endTime":"0","summary":"Analyst Sara Nik of H.C. Wainwright reiterated a Buy rating on Pasithea Therapeutics Corp, retaining the price target of $3.00. Sara Nik has given ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/pasithea-therapeutics-buy-rating-on-differentiated-pas-004-2026-clinical-catalysts-and-strengthened-cash-runway-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/pasithea-therapeutics-buy-rating-on-differentiated-pas-004-2026-clinical-catalysts-and-strengthened-cash-runway-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2603686640","title":"Pasithea Therapeutics Announces Data Release Timeline for PAS-004 Clinical Trials in NF1 and Advanced Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686640","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686640?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:02","pubTimestamp":1768305720,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corporation announced updates on its clinical development programs for PAS-004, a next-generation oral macrocyclic MEK inhibitor. The company has completed enrollment of 12 patients in the first four dose cohorts of its Phase 1/1b clinical trial  in adult patients with neurofibromatosis type 1 associated plexiform neurofibromas . Pasithea plans to present safety, tolerability, pharmacokinetic, and efficacy data, including six-month outcomes for both plexiform and cutaneous neurofibromas, in the second half of 2026. Additionally, in its ongoing Phase 1 clinical trial in advanced cancer patients , Pasithea expects to present longer-term follow-up data from Cohorts 4 through 8 in the second quarter of 2026. Results from these studies have not yet been presented and will be released in the future according to the company’s outlined timelines.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL8jYNDG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014005.SGD","BK4112","SG9999014013.SGD","SG9999014039.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","KTTA","BK4139","SG9999014021.USD"],"gpt_icon":0},{"id":"2603686669","title":"Pasithea Therapeutics Corp - to Present Nf1-Pn Study Data in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686669","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686669?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:01","pubTimestamp":1768305696,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YD1RI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2603686905","title":"Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686905","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686905?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:01","pubTimestamp":1768305660,"startTime":"0","endTime":"0","summary":"MIAMI, Jan.  13, 2026  (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral m","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/13/3217645/0/en/Pasithea-Therapeutics-Provides-Outlook-on-PAS-004-Clinical-Programs-and-Data-Release-Timelines.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4181","BK4218","LU1169589451.USD","LU1169590202.USD","KTTA","BK4139"],"gpt_icon":0},{"id":"2602607425","title":"Pasithea Therapeutics Unveils Investor Presentation Highlighting Next-Generation MEK Inhibitor PAS-004 for Cancer and NF1","url":"https://stock-news.laohu8.com/highlight/detail?id=2602607425","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602607425?lang=en_us&edition=fundamental","pubTime":"2026-01-12 12:26","pubTimestamp":1768191993,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corporation has released a new investor presentation outlining the company’s current pipeline and ongoing clinical programs. The presentation provides updates on the development, manufacturing, and commercialization plans for its product candidates, including details on PAS-004 and the design and enrollment of its ongoing Phase 1 and Phase 1/b clinical trials in advanced cancer patients. Information is also provided regarding cash needs, projected cash runway, and current operating plans. The document includes data on market size and industry comparisons. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the origi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL2sSMVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2592190534","title":"Pasithea Therapeutics Corporation Announces Date for Upcoming Special Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2592190534","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592190534?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:31","pubTimestamp":1766179912,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp. has announced that it will hold a Special Meeting of Stockholders in a virtual format on January 28, 2026. During the meeting, stockholders will vote on proposals including an increase to the company’s authorized shares and an amendment to the 2023 Incentive Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL9RgcVW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2589584453","title":"Pasithea Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2589584453","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589584453?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:52","pubTimestamp":1765198320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KTTA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 07:52 ET (12:52 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2589330469","title":"HC Wainwright Initiates Coverage on Pasithea Therapeutics With Buy Rating, $3 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2589330469","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589330469?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:23","pubTimestamp":1765196627,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics (KTTA) has an average rating of Buy and mean price target of $3, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KTTA","BK4139"],"gpt_icon":0},{"id":"2589334034","title":"Pasithea Therapeutics Corp. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2589334034","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589334034?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:11","pubTimestamp":1765192297,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nAZN4RBR9C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"gpt_icon":0},{"id":"2588030390","title":"Press Release: Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2588030390","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588030390?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676800,"startTime":"0","endTime":"0","summary":"-- Extends cash runway through at least the first half of 2028. -- Led by healthcare-dedicated investors, including Vivo Capital, Janus. Investments, Adage Capital Partners and Squadron Capital Management. MIAMI, Dec. 02, 2025  -- Pasithea Therapeutics Corp.  , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas , today announced the closing of its previously announced public offering of 80,000,000 shares of the Company's common stock  at an offering price of $0.75 per share of common stock . The public offering was led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Management.H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.This press release does not constitute an offer to sell or the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"7a5901a9f1bb5fc4fa7bc7230f7ede9b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4139","BK4218","LU1169589451.USD","LU1169590202.USD","PK","BK4181","PD","KTTA"],"gpt_icon":1},{"id":"1100736610","title":"Form 4 | Pasithea Therapeutics Corp. Director Lawrence Steinman purchased 133,333 Shares.","url":"https://stock-news.laohu8.com/highlight/detail?id=1100736610","media":"Filings Track","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100736610?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:10","pubTimestamp":1764598216,"startTime":"0","endTime":"0","summary":"Lawrence Steinman, Director of Pasithea Therapeutics Corp. (Ticker: KTTA), on November 28, 2025, purchased 133,333 shares of common stock at a price of $0.75 per share. After the transaction, Mr....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA"],"gpt_icon":1},{"id":"2588731427","title":"Pasithea Therapeutics Director Lawrence Steinman Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588731427","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588731427?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:07","pubTimestamp":1764598066,"startTime":"0","endTime":"0","summary":"Lawrence Steinman, Director of Pasithea Therapeutics Corporation, has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL4n0CSH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"gpt_icon":1},{"id":"2588773889","title":"Pasithea Therapeutics Director Simon Dumesnil Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588773889","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588773889?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:54","pubTimestamp":1764597286,"startTime":"0","endTime":"0","summary":"Simon Dumesnil, Director of Pasithea Therapeutics Corporation, reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL24yJdz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Pasithea Therapeutics Director Simon Dumesnil Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"gpt_icon":1},{"id":"2587734171","title":"US Equity Markets Close Higher During Thanksgiving Week as Interest Rate Cut Expectations Remain Strong","url":"https://stock-news.laohu8.com/highlight/detail?id=2587734171","media":"MT Newswires Live","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587734171?lang=en_us&edition=fundamental","pubTime":"2025-11-29 02:52","pubTimestamp":1764355965,"startTime":"0","endTime":"0","summary":"US equity indexes closed higher Friday despite a losing month amid broad market gains during the Thanksgiving week, as expectations for a Federal Reserve interest rate cut in December remained strong.* The likelihood of a 25-basis-point interest rate cut in December rose to 87% from 83.4% on Wednesday, according to the CME FedWatch Tool.* The Chicago Mercantile Exchange resumed operations following an outage due to a server cooling problem that disrupted futures trading of various asset classes, including equities, on Friday.* January West Texas Intermediate crude oil rose $0.86 to settle at $56.52 per barrel, while January Brent crude, the global benchmark, was last seen up $0.07 to $63.41.* Pasithea Therapeutics  said Friday it priced a public offering of 80 million shares or pre-funded warrants at $0.75 each for expected gross proceeds of about $60 million, and the stock was up roughly 39%.* Tilray Brands'  shares dropped nearly 21% after the company said late Wednesday that it will","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"3cb4a431655b8884ac8b0160e9ed202a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4139","SQQQ","KTTA","DOG","TSYW.SI",".DJI","BK4596","BK4585","NVIW.SI",".IXIC","TLRY","NQmain","QID","UDOW","DDM","EQR","BK4557","BK4547","MNQmain","BK4588","SDOW","TQQQ","USAW.SI","USJW.SI","DXD","MYMmain","QLD","BK4215","DJX","PSQ",".SPX"],"gpt_icon":1},{"id":"2587731921","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2587731921","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587731921?lang=en_us&edition=fundamental","pubTime":"2025-11-29 01:48","pubTimestamp":1764352135,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics  reported Friday it priced a public offering of 80 million shares or pre-funded warrants at $0.75 each, targeting $60 million in gross proceeds.The net proceeds will be used for general corporate purposes, including research, clinical trials, and potential acquisitions or licensing activities.Shares surged 54% as intraday trading volume catapulted to over 155.3 million from a daily average of about 3.9 million.HeartBeam  said late Wednesday it received a \"Not Substantially Equivalent\" decision from the US Food and Drug Administration on its 12-lead ECG synthesis software submission, and said it is actively engaging with the agency on multiple regulatory paths, including potential labeling modifications.The company said its supporting clinical study met its endpoints and believes remaining FDA concerns can be addressed.Shares jumped 24%, with intraday trading volume at over 96.9 million compared with a daily average of about 425,000.Price: 1.63, Change: +0.57, Perc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BEAT","BK4139","KTTA","BK4082"],"gpt_icon":0},{"id":"2587859739","title":"Crude Oil Gains 1%; Tilray Brands Shares Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=2587859739","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587859739?lang=en_us&edition=fundamental","pubTime":"2025-11-29 00:27","pubTimestamp":1764347270,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/11/49117855/crude-oil-gains-1-tilray-brands-shares-plunge","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NVIW.SI",".IXIC","PSQ","BEAT","RUBI","DEFT","BK4087","BK4547","MNQmain","SQQQ","QLD","TLRY","BK4144","BK4557","LU0348767384.USD","BK4007","KTTA","USAW.SI","QID","NQmain","LU0348766576.USD","BK4596","BK4135","TSYW.SI","USJW.SI","ANPA","TQQQ","BK4610","BK4526","BK4539","BK4139"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.pasithea.com","stockEarnings":[{"period":"1week","weight":-0.0546},{"period":"1month","weight":0.1291},{"period":"3month","weight":-0.3258},{"period":"6month","weight":0.0668},{"period":"1year","weight":-0.3199},{"period":"ytd","weight":-0.3937}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.182441},{"month":2,"riseRate":0.4,"avgChangeRate":-0.152614},{"month":3,"riseRate":0.4,"avgChangeRate":-0.006058},{"month":4,"riseRate":0.25,"avgChangeRate":0.021877},{"month":5,"riseRate":0.25,"avgChangeRate":-0.227944},{"month":6,"riseRate":0.5,"avgChangeRate":0.06208},{"month":7,"riseRate":1,"avgChangeRate":0.10295},{"month":8,"riseRate":0.5,"avgChangeRate":-0.003687},{"month":9,"riseRate":0.5,"avgChangeRate":-0.003936},{"month":10,"riseRate":0.2,"avgChangeRate":-0.132455},{"month":11,"riseRate":0.4,"avgChangeRate":0.147256},{"month":12,"riseRate":0.4,"avgChangeRate":-0.165941}],"exchange":"NASDAQ","name":"Pasithea Therapeutics Corp.","nameEN":"Pasithea Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pasithea Therapeutics Corp.(KTTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pasithea Therapeutics Corp.(KTTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pasithea Therapeutics Corp.,KTTA,Pasithea Therapeutics Corp.股票,Pasithea Therapeutics Corp.股票老虎,Pasithea Therapeutics Corp.股票老虎国际,Pasithea Therapeutics Corp.行情,Pasithea Therapeutics Corp.股票行情,Pasithea Therapeutics Corp.股价,Pasithea Therapeutics Corp.股市,Pasithea Therapeutics Corp.股票价格,Pasithea Therapeutics Corp.股票交易,Pasithea Therapeutics Corp.股票购买,Pasithea Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pasithea Therapeutics Corp.(KTTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pasithea Therapeutics Corp.(KTTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}